 Your new post is loading...
Your new post is loading...
Scoop.it!
More pharma news ... BioLineRx says it has positive pre-clinical results for a drug called BL-9020, a novel monoclonal antibody treatment for Type 1 diabetes. From Smarter Analyst: BL-9020 is a nov... 
No comment yet.
Sign up to comment
Scoop.it!
The genes that increase the risk of Type 1 diabetes have lost their hiding place.
Scoop.it!
High Diversity in the TCR Repertoire of GAD65 Autoantigen-Specific
|
|
Scooped by
Gilbert C FAURE
March 1, 2015 2:32 PM
|
Scoop.it!
Measuring autoantibodies in the blood may indicate whether the immune system has begun to attack its own insulin cells.
The new findings from the NIH-funded study, which were recently published in Diabetologia, suggest three ways of predicting development of type 1 diabetes.
If the autoantibody first discovered attacks insulin (IAA). In the study as a whole, this occurred by age 1 year. Dr. Lernmark noted in the release that if a second autoantibody is detected, the person may develop diabetes but perhaps not for 20 years.If the first autoantibody targets GAD65 (GADA), a protein inside the insulin-producing cells. This was most common at age 2 years in the study.If both autoantibodies are first found together. According to Dr. Lernmark, 40% of these children in the TEDDY study had already developed diabetes.In the study, participants were enrolled as infants and underwent quarterly standardized autoantibody assessments for the first 4 years of life and semi-annually thereafter.
|
|
Scooped by
Gilbert C FAURE
February 22, 2015 3:57 AM
|
Scoop.it!
An MRI-based imaging technique may reveal inflammation that will give more insight into diabetes risk and treatment strategies.
imaging vs autoantibodies
|
|
Scooped by
Gilbert C FAURE
February 16, 2015 1:20 PM
|
Scoop.it!
In recent years, growing understanding of diabetes has led to its recognition as a multifaceted disease that cannot simply be dichotomized into its 2 most common subgroups.
|
|
Scooped by
Gilbert C FAURE
February 8, 2015 2:21 PM
|
Scoop.it!
Changes in gut microbiota appear to be associated with the onset of type 1 diabetes, according to findings published in Cell, Host & Microbe.
|
|
Scooped by
Gilbert C FAURE
February 5, 2015 3:09 PM
|
Scoop.it!
Authors: Susanna Hamari, Tiina Kirveskoski, Virpi Glumoff, Petri Kulmala, Olli Simell, Mikael Knip, Jorma Ilonen, Riitta Veijola, Discipline: Medicine, Type: Journal Article
|
|
Scooped by
Gilbert C FAURE
January 31, 2015 2:41 PM
|
Scoop.it!
The UM Miller School of Medicine serves South Florida, South America and the Caribbean in education, research and patient care.
A well-deserved award for the whole nPOD initiative.
|
|
Scooped by
Gilbert C FAURE
January 25, 2015 2:00 PM
|
Scoop.it!
The association of cytotoxic T-lymphocyte antigen-4 + 49A/G and CT60 polymorphisms with type 1 diabetes and la... http://t.co/uQ6YL50x0G
|
|
Scooped by
Gilbert C FAURE
January 22, 2015 3:32 AM
|
Scoop.it!
A new approach developed by researcher Thomas Burris, Ph.D., stops the destruction of beta cells and preserves insulin production.
|
|
Scooped by
Gilbert C FAURE
January 20, 2015 4:39 AM
|
Scoop.it!
The Diabetes Virus Detection study (DiViD) is the first to examine fresh pancreatic tissue at the diagnosis of type 1 diabetes for the presence of viruses. Minimal pancreatic tail resection was performed 3-9 weeks after onset of type 1 diabetes in 6 adult patients (age 24-35 years). The presence of enteroviral capsid protein 1 (VP1) and the expression of class I HLA were investigated by immunohistochemistry.
|
|
Rescooped by
Gilbert C FAURE
from diabetes and more
January 12, 2015 9:17 AM
|
Scoop.it!
The American Diabetes Association has awarded La Jolla Institute researcher Stephanie Stanford, Ph.D., a $1.6 million grant to investigate the genetic and environmental factors that trigger the onset of type 1 diabetes.
PTPN22 http://www.ncbi.nlm.nih.gov/gene/26191
This gene encodes of member of the non-receptor class 4 subfamily of the protein-tyrosine phosphatase family. The encoded protein is a lymphoid-specific intracellular phosphatase that associates with the molecular adapter protein CBL and may be involved in regulating CBL function in the T-cell receptor signaling pathway. Mutations in this gene may be associated with a range of autoimmune disorders including Type 1 Diabetes, rheumatoid arthritis, systemic lupus erythematosus and Graves' disease. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Mar 2009]
"We believe that when the PTPN22 gene is mutated, it impairs the body's immune response to viral infections, especially a specific enterovirus that is known to trigger type 1 diabetes by leaving the body vulnerable to an attack on the pancreas," Dr. Stanford said. "We also believe that certain environmental factors, including exposure to pathogens early in life, contribute to increased risk of type 1 diabetes."
|
|
Scooped by
Gilbert C FAURE
March 11, 2015 2:53 PM
|
Scoop.it!
IPEX is a very rare syndrome marked by aggressive autoimmunity and usually results in early death: http://t.co/syufgKmWks
|
|
Scooped by
Gilbert C FAURE
March 10, 2015 2:45 PM
|
Scoop.it!
The genes that increase the risk of Type 1 diabetes have lost their hiding place, scientists report. A research group has located and narrowed down the number of genes that play a role in the disease, according to their study.
|
|
Scooped by
Gilbert C FAURE
March 1, 2015 2:41 PM
|
Scoop.it!
Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.
|
|
Scooped by
Gilbert C FAURE
February 23, 2015 3:30 PM
|
Scoop.it!
Discovery of Native Autoantigens via Antigen Surrogate
Technology: Application to Type 1 Diabetes http://t.co/BckOv5BOeP
|
|
Scooped by
Gilbert C FAURE
February 16, 2015 1:25 PM
|
Scoop.it!
Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.
|
|
Scooped by
Gilbert C FAURE
February 14, 2015 4:12 AM
|
Scoop.it!
Proc Natl Acad Sci U S A. 2015 Feb 9. pii: 201424934. [Epub ahead of print]
|
|
Scooped by
Gilbert C FAURE
February 7, 2015 2:20 PM
|
Scoop.it!
The next decade could see the development of a vaccine for type 1 diabetes, which could be given to infants or those with a susceptibility to the disease
|
|
Scooped by
Gilbert C FAURE
February 4, 2015 1:57 PM
|
Scoop.it!
Clin Immunol. 2014 Jul;153(1):23-30. doi: 10.1016/j.clim.2014.03.016. Epub 2014 Apr 1. Clinical Trial; Research Support, Non-U.S. Gov't
|
|
Scooped by
Gilbert C FAURE
January 28, 2015 1:44 PM
|
Scoop.it!
by Robert Z. Harms, Kristina M. Lorenzo, Kevin P. Corley, Monina S. Cabrera, Nora E. Sarvetnick
Type 1A diabetes (T1D) is believed to be caused by immune-mediated destruction of β-cells, but the immunological basis for T1D remains controversial.
|
|
Scooped by
Gilbert C FAURE
January 22, 2015 9:20 AM
|
Scoop.it!
King’s College London announced that it has entered an exclusive licence agreement with UCB that grants the company the rights to develop a peptide-based immunotherapy programme for type 1 diabetes.
|
|
Scooped by
Gilbert C FAURE
January 20, 2015 7:21 AM
|
Scoop.it!
– First Ever Person with Type 1 Diabetes Receives Experimental Encapsulated Human Stem Cell-Derived Beta Cell Replacement Therapy – New York, NY, October 29, 2014 — JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D)...
belated sorry
About JDRF
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence and a working plan to bring life-changing therapies from the lab to the community. As the largest charitable supporter of T1D research, JDRF is currently sponsoring $568 million in charitable research in 17 countries. For more information, please visit www.jdrf.org
|
|
Scooped by
Gilbert C FAURE
January 16, 2015 2:25 PM
|
Scoop.it!
Harvard researchers at Brigham and Women’s Hospital have uncovered a way to enhance and prolong the therapeutic effects of mesenchymal stem cells in a preclinical model of type 1 diabetes.
BL-9020 targets NKp46, a unique target that is involved in the innate response against the pancreas. Pre-clinical studies in mouse models of Type 1 diabetes suggest that BL-9020 can inhibit beta cell death, thus preventing full maturation of the disease. This effect could significantly delay, and potentially prevent, the need for chronic insulin use by Type 1 diabetes patients, as well as provide a potential benefit in minimizing diabetes-related complications.
The new set of experiments shows that BL-9020 led to decreased levels of its target, NKp46, on murine NK cells, and specifically reduces the cytotoxic activity mediated by NKp46 in these cells.